D
David Brachman
Researcher at Barrow Neurological Institute
Publications - 107
Citations - 9282
David Brachman is an academic researcher from Barrow Neurological Institute. The author has contributed to research in topics: Radiation therapy & Temozolomide. The author has an hindex of 38, co-authored 102 publications receiving 8007 citations. Previous affiliations of David Brachman include St. Joseph's Hospital and Medical Center & University of Chicago.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert,James J. Dignam,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Deborah T. Blumenthal,Michael A. Vogelbaum,Howard Colman,Arnab Chakravarti,Stephanie L. Pugh,Minhee Won,Robert Jeraj,Paul D. Brown,Kurt A. Jaeckle,David Schiff,Volker W. Stieber,David Brachman,Maria Werner-Wasik,Ivo W. Tremont-Lukats,Erik P. Sulman,Kenneth Aldape,Walter J. Curran,Minesh P. Mehta +22 more
TL;DR: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.
Journal ArticleDOI
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Gregory Cairncross,Meihua Wang,Edward G. Shaw,Robert B. Jenkins,David Brachman,Jan C. Buckner,Karen Fink,Luis Souhami,Normand Laperriere,Walter J. Curran,Minesh P. Mehta +10 more
TL;DR: For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
Journal ArticleDOI
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner,Edward G. Shaw,Stephanie L. Pugh,Arnab Chakravarti,Mark R. Gilbert,Geoffrey R. Barger,Stephen W. Coons,Peter Ricci,Dennis E. Bullard,Paul D. Brown,Keith J. Stelzer,David Brachman,John H. Suh,Christopher J. Schultz,Jean Paul Bahary,Barbara Fisher,Barbara Fisher,Harold Kim,Albert Murtha,Erica Hlavin Bell,Minhee Won,Minesh P. Mehta,Walter J. Curran +22 more
TL;DR: In a cohort of patients with grade 2 glioma who were younger than 40 years of age and had undergone subtotal tumor resection or who were 40 yearsof age or older, progression-free survival and overall survival were longer among those who received combination chemotherapy in addition to radiation therapy than amongThose who received radiation therapy alone.
Journal ArticleDOI
Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol
Luis Souhami,W. Seiferheld,David Brachman,Ervin B. Podgorsak,Maria Werner-Wasik,Robert H. Lustig,Christopher J. Schultz,William T. Sause,Paul Okunieff,Jan C. Buckner,Lucia Zamorano,Minesh P. Mehta,Walter J. Curran +12 more
TL;DR: Stereotactic radiosurgery followed by EBRT and BCNU does not improve the outcome in patients with GBM nor does it change the general quality of life or cognitive functioning.
Journal ArticleDOI
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
J. Gregory Cairncross,Meihua Wang,Robert B. Jenkins,Edward G. Shaw,Caterina Giannini,David Brachman,Jan C. Buckner,Karen Fink,Luis Souhami,Normand Laperriere,Jason T. Huse,Minesh P. Mehta,Walter J. Curran +12 more
TL;DR: IDH mutational status identified patients with oligodendroglial tumors who did (and did not) benefit from alkylating-agent chemotherapy with RT, and although patients with codeleted tumors lived longest, patients with noncodeleted IDH-mutated tumors also lived longer after CRT.